Company Product Description Indication Status
Cue Health Inc., of San Diego, Calif. Cue COVID-19 test Lower nasal swab point-of-care test Molecular detection of the SARS-CoV-2 virus Mayo Clinic study evaluated the test's accuracy against the centralized lab PCR testing model in samples from 292 patients in a point-of-care setting; found that the overall concordance between the Cue test and the reference laboratory tests was 97.8%; Cue test was positive in 91.7-95.7% of patients who tested positive by the reference method; 98.4% of patients who received a negative reference result also obtained negative results by Cue Health; study was published in Diagnostic Microbiology and Infectious Diseases
Magnolia Medical Technologies Inc., of Seattle Steripath Gen2 initial specimen diversion device (ISDD) User-controlled negative pressure diverts and sequesters the initial 1.5 to 2.0 mL of blood collected for culture Reduces blood culture contamination and false-positive central line-associated bloodstream infection (CLABSI) rates Presented phase I study results; reported 0.0% blood culture contamination events; had 0.0% false-positive CLABSIs out of 4,462 blood cultures drawn with the Steripath Gen2 ISDD during a 4-month study vs. a 3.15% contamination rate (29 contamination events in 922 blood cultures) using the standard method

Notes

For more information about individual companies and/or products, see Cortellis.